Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder

Loading...
Loading...
  • The FDA has granted priority review status to Amryt Pharma's AMYT marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB).
  • Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare genetic skin disorder characterized by blistering lesions on the skin and mucous membranes.
  • In general, the FDA's Priority Review designation accelerates the review time from ten months to a goal of six months from the date of acceptance of the filing.
  • The FDA has set a target action date of November 30.
  • Oleogel-S10 had previously received Fast Track Designation and Rare Pediatric Disease Designation from the FDA. If the NDA for Oleogel-S10 is approved, the company will apply for a priority review voucher.
  • "Confirmation of a target PDUFA date of November 30 keeps us on track for potential approval this year," said CEO Joe Wiley.
  • Yesterday, the FDA accepted for review the company's Oleogel-S10 marketing application. The agency had informed that notification of any filing review issues, including priority review determination and target action date, would be provided by June 12.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: AMYT shares closed at $11.65 on Wednesday.
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefsEpidermolysis BullosaSkin Disorder
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...